Report: Oxford Covid-19 Vaccine Is lesser Effective Than South African Variant

Advertisement

On Saturday, British drugmaker AstraZeneca said its University of Oxford vaccine tended to provide only modest safety against mild diseases caused by the South African version of COVID-19. This is in accordance with early trial results and data.

According to an article published previously in the day, the research from South Africa’s University of the Witwatersrand and Oxford University showed that the vaccine had substantially decreased efficacy against the South African version.

The so-called British, South African, and Brazilian strains, which tend to spread more rapidly than others, are one of the coronavirus variants currently most important and concerning for scientists and public health experts.

Advertisement

Image result for Report: Oxford Covid-19 Vaccine Is less Effective Than South African Variant
Hindustan Times

“In this small phase I/II trial, early data has shown limited efficacy against mild disease primarily due to the B.1.351 South African variant,” an AstraZeneca spokesman said in response to the report.

The article we talked about said that not more than 2,000 participants who participated in the trial had been hospitalized or died.

More About Statements By Oxford And Report:

Oxford said on Friday that their vaccine has equal effectiveness against the British strain of coronavirus. It is because of what it does against the strains previously existing.

Advertisement

“However, we have not been able to properly ascertain its effect against severe disease and hospitalization gave that subjects were predominantly young healthy adults,” the AstraZeneca spokesman said.

The company claimed that it assumed that its vaccine could protect against severe diseases, provided that the efficacy of the neutralizing antibody was similar to that of other COVID-19 vaccines that have been shown to protect against serious diseases.

The article said that the research and trial, involving 2,026 individuals among whom half shaped the placebo group, was not peer-reviewed.

Although thousands of individual changes have occurred as the infection spreads through its recent new forms, according to the British Medical Journal, only a tiny minority are expected to be significant or modify the virus in a meaningful fashion.

“Oxford University and AstraZeneca have started adapting the vaccine against this variant and will advance rapidly through clinical development so that it is ready for Autumn delivery should it be needed,” the AstraZeneca spokesman said.

Advertisement
Parth Dubey
Parth Dubey
I am Parth Dubey, currently an undergraduate. I have been working as a content writer for the past 6 months and have worked in various fields with many people and firms. I firmly believe that writing is not just about money making or attracting people, it's more about knowledge and information, along with feelings.

Must Read

Amitabh Bachchan Posts About His Health, Undergoing A Surgery

In his most recent blog post, Bollywood legend Amitabh Bachchan gave an update on his health, disclosing that he had surgery due to a...

Chief Scientist of the WHO: More Testing Is Necessary